Clinical guidelines for IVF with PGD for HLA matching

Area of Science:

• Reproductive Medicine
• Immunogenetics
• Stem Cell Transplantation

Background:

• Hematopoietic stem cell transplantation (HSCT) offers improved survival rates when using matched related donors.
• A significant majority of patients (70%) lack access to matched related donors for HSCT.
• Preimplantation genetic diagnosis for human leukocyte antigen (PGD-HLA) typing presents a viable alternative for selecting a donor.

Purpose of the Study:

• To evaluate the clinical utility and ethical considerations of in vitro fertilization (IVF) with PGD-HLA for creating a matched donor.
• To discuss the appropriate timing and patient selection for IVF with PGD-HLA.
• To advocate for clinical guidelines and collaborative efforts to support this procedure.

Main Methods:

• Utilizes in vitro fertilization (IVF) combined with preimplantation genetic diagnosis (PGD) for human leukocyte antigen (HLA) typing.
• Involves genetic screening of embryos to identify a human leukocyte antigen (HLA)-matched donor for a sibling requiring hematopoietic stem cell transplantation (HSCT).
• Considers the use of related half-matched egg donors as an alternative.

Main Results:

• Successful HSCT has been achieved using stem cells from children conceived via PGD-HLA.
• Children born through this process demonstrate excellent health and receive strong family support.
• The success of PGD-HLA supports its role as a 'gift of life' rather than a 'designer baby' concern.

Conclusions:

• IVF for PGD-HLA is a clinically relevant option for families needing a matched donor for HSCT when none is available.
• Discussions regarding IVF for PGD-HLA should occur with families when a matched donor is absent, HSCT is feasible within 9-12 months, and the mother is of reproductive age.
• Establishing national/international collaborations and referring couples to experienced centers are crucial for successful implementation and improved patient care.